Current responsibilities
Mr. Schroeder joined JLL as a Senior Vice President in November 2015 and is based in the firm’s MetroPark, NJ office. Mr. Schroeder provides over 20+ years of commercial real estate experience in strategic planning, lease negotiations and transaction services. He has completed major transactions in the Pharmaceutical/Life Sciences, Engineering and higher education industries where he has completed over 25 million square feet of transactions.
Experience
Mr. Schroeder’s primary focus is in the Life Sciences. He is a leader of JLL’s Global Life Science Practice Group and has completed numerous transactions in the fast-growing gene therapy and biologics areas for clients such as Catalent Pharma, Beam Therapeutics and others.
Prior to his real estate career Mr. Schroeder worked for Novartis Pharmaceuticals for 10 years and brought his experience in the Life Sciences field to his real estate career representing companies such as LabCorp, Novartis, Syneos Health and many more.
- Catalent Pharmaceuticals: Portfolio manager 7m SF
- Cephalon: Headquarters assignment for 250,000 SF
- LabCorp: 400,000 SF, diagnostics facilities
- Aurobindo Pharma: US Headquarters for 110,000 SF
- Eurofins: 200,000 SF consolidation
- Syneos Health: 250,000 SF, multiple locations
- Rubicon Research: 200,000 SF OSD Build-to-suit
- Ciba Specialty Chemicals: Various assignments for 500,000 SF
- Beam Therapeutics: 100,000 SF gene therapy manufacturing
- Louis Berger Group: 100,000 SF HQ relocation
- Lincoln Education: 2.3 million SF portfolio
- Mott MacDonald: Portfolio transactions for 200,000 SF
- Evotec: 50,000 SF US expansion
Representative clients
- Catalent Pharmaceuticals
- Beam Therapeutics
- LabCorp
- Aurobindo Pharmaceuticals
- Merck
- Hikma Pharmaceuticals
- Achilles Therapeutics
- Eurofins Scientific
- Rubicon Research
- Evotec
- Novitium Pharma
- BNP Paribas
- Mott MacDonald
- Louis Berger Group
- Lincoln Education
- Lord Abbett
- Syneos Health
